A meta-analysis of 3 placebo-controlled randomized clinical trials involving 9,013 patients with heart failure with reduced or mildly reduced ejection fraction found that treatment with digitalis glycosides was associated with a lower risk of cardiovascular death or first worsening heart failure event compared with placebo, primarily through fewer worsening heart failure events. The reduction in the primary composite endpoint was consistent across treatment eras and types of digitalis glycosides, although researchers found no reduction in cardiovascular or all-cause mortality.